Kornimate/medical-research-clean huggingface dataset:
tregs cd25 cxcl9 in vitiligo

Conditions: Vitiligo; CD25 Deficiency; Chemokine (C-X-C Motif); Tregs

Summary: clinical significance of circulating t regulatory cells , soluble cd25 and cxcl9 to assess disease activity of vitiligo.

vitiligo is an acquired and polygenic skin depigmenting disease characterized by bilateral, symmetrical depigmented patches over the entire body. its pathogenesis is multifactorial; however, the exact mechanisms that integrate the individual genetic susceptibility, melanocyte auto aggression, and failure of immune tolerance mechanisms are still not fully understood. the presence of these autoreactive cd8+ and cd4+ t cells in vitiligo patients' skin and blood samples . indicates a dysregulation of regulatory t-cell mechanism, which can suppress these cells. previous studies have reported an altered treg cell frequency and function in vitiligo patients. foxp3 is the key transcriptional regulators of tregs which mediate treg cell function by repressing the expression of cytokines (il2 and il4 ) and upregulate the treg cell markers (ctla-4 and cd25 ). expression of il-2 and its receptor cd25 are the most fundamental events in the host immune response. thus any disorder in which t lymphocyte activation occurs at a substantial level is expected to induce expression of cd25 beyond ambient levels; this had been reported in atopic asthma, multiple sclerosis, allergic responses. cd4+ cd25 foxp3+ tregs are important in maintaining self-tolerance and regulating immune responses in both physiological and pathological conditions . chemokines are important inflammatory factors that participate in many autoimmune responses. c-x-c motif chemokine ligand 9 (cxcl9) is linked to the th1 pattern and has been suggested as one of the most relevant chemokine axes that promote t-cell migration in different autoimmune and inflammatory processes. in vitiligo, cxcl9 has been suggested to promote melanocyte-specic ctls to in ltrate into the basal layer of the epidermis to attack melanocytes, resulting in the deficiency of melanin.

Eligibility criteria:
inclusion criteria:the patients will be enrolled in the study if they have :- * non segmental vitiligo. exclusion criteria: the following patients were excluded from this study: * patients receiving systemic treatment in the last two months. * patients with any autoimmune disease, such as rheumatoid arthritis. inflammatory bowel disease, psoriasis, or systemic lupus erythematosus; patients with type 1 diabetes mellitus. * patients with any thyroid and/or neoplastic diseases.
examining the effectiveness of carbohydrate loading as a nursing intervention in enhanced recovery after surgery

Conditions: Cardiovascular Diseases

Summary: the concept of enhanced recovery after surgery (eras) protocols has revolutionized perioperative care by promoting a series of evidence-based practices aimed at reducing surgical stress and improving patient outcomes. among these practices, preoperative carbohydrate loading has emerged as a significant intervention designed to mitigate the adverse metabolic effects of surgery


Eligibility criteria:
inclusion criteria: - cardiovascular disease exclusion criteria: insulin dependent diabetes -
safety and efficacy of alxn1720 in adults with generalized myasthenia gravis

Conditions: Generalized Myasthenia Gravis

Summary: the purpose of this study is to evaluate the safety and efficacy of alxn1720 for the treatment of generalized mg (gmg) in adults with autoantibodies against acetylcholine receptor (achr).


Eligibility criteria:
inclusion criteria: * diagnosis of mg with generalized muscle weakness meeting the clinical criteria defined by myasthenia gravis foundation of america (mgfa) class ii, iii or iv * positive serological test for autoantibodies against achr exclusion criteria: * history of thymectomy, or any other thymic surgery within 12 months prior to screening * untreated thymic malignancy, carcinoma, or thymoma * history of neisseria meningitidis infection * pregnancy, breastfeeding, or intention to conceive during the course of the study

Keywords: alxn1720 anti-acetylcholine receptor antibody-positive acetylcholine receptor achr generalized myasthenia gravis myasthenia gravis mg gmg complement component 5 c5 vhh antibody
lateral wedge insole with subtalar strapping for knee osteoarthritis

Conditions: Osteoarthritis

Summary: this is a clinical study to evaluate the efficacy of a lateral wedge insole with subtalar strapping in knee osteoarthritis treatment.

the objective of this study is to evaluate the efficacy of a lateral wedge insole with subtalar strapping in knee osteoarthritis treatment. fifty-eight patients with knee osteoarthritis were randomized to use either a lateral wedge or a neutral insole. vas, western ontario and mcmaster universities osteoarthritis index (womac) and lequesne questionnaires were applied at baseline, and weeks two, eight, and 24.

Eligibility criteria:
inclusion criteria: * meet the american college of rheumatology criteria for knee osteoarthritis * varus malalignment of the knee * absence of previous fracture on the index knee * absence of previous surgery on the index knee * absence of rheumatoid arthritis * no intra-articular injection on the index knee in the past 6 months * receiving usual care for osteoarthritis for at least 6 months * be able to understand and agree with the informed consent exclusion criteria: * undergo surgery during the study * undergo intra-articular injection during the study * develop articular infection of the index joint during the study

Keywords: osteoarthritis osteoarthritis, knee foot orthoses orthotic insoles
a prospective real-world multi-center post-market observational evaluation of supersaturated o2 therapy using the therox® downstream® system

Conditions: Anterior Acute Myocardial Infarction (AMI)

Summary: the purpose of this study is to collect real-world data on the therox downstream system® to assess the effectiveness and cost- effectiveness of sso2 therapy, compared with pci alone for treatment of patients with acute anterior mi.


Eligibility criteria:
inclusion criteria: 1. men or women aged 18 years or older. 2. presentation with anterior acute st-elevation myocardial infarction (\> 1 mm st-segment elevation in two or more contiguous leads between v1 and v4). 3. the primary stented infarct-related lesion(s) must be in the proximal and/or mid-lad coronary artery (other lesions may be treated if clinically indicated). 4. successful angioplasty within 6 hours of symptom onset, as documented by \<50% diameter residual angiographic stenosis within all treated culprit lesions with timi 2 or 3 flow and no major complications such as perforation or shock. 5. the patient or their legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided and signed written informed consent, approved by the appropriate institutional review board (irb). 6. patient and his/her physician agree to all required follow-up procedures and visits. exclusion criteria: 1. ipsilateral insertion of a second sheath in a single femoral artery for supersaturated oxygen therapy is strictly contraindicated. 2. presence of an intra-aortic balloon pump. 3. proximal coronary stenosis that would restrict flow with the sso2 catheter in place 4. presence of a post-intervention non-stented coronary dissection or perforation. 5. cardiac valvular stenosis or insufficiency, pericardial disease or non-ischemic cardiomyopathy. 6. pregnant or nursing women. 7. cardiogenic shock. 8. patients contraindicated for anticoagulation therapy. 9. patients with ventricular pseudoaneurysm, vsd, or severe mitral valve regurgitation (with or without papillary muscle rupture). 10. hemoglobin \< 10 g/dl. 11. gastrointestinal or genitourinary bleeding within the last two months, or any major surgery (including cabg) within six weeks of procedure. 12. patients with active covid-19 infection.
a study to evaluate the efficacy and safety of imsidolimab (anb019) in adults with palmoplantar pustulosis

Conditions: Palmoplantar Pustulosis

Summary: a study to evaluate the efficacy and safety, and pharmacokinetic (pk) profile of multiple doses of imsidolimab (anb019) in adults with palmoplantar pustulosis (ppp)


Eligibility criteria:
inclusion criteria: * clinically confirmed diagnosis of ppp * disease duration of at least 6 months prior to screening * present with active pustules on palms or/and soles at screening exclusion criteria: * any other ongoing inflammatory disease that interfere with the investigator's ability to evaluate the subject's response to therapy * history of recurrent or active/serious infection * ongoing use of psoriasis prohibited medication other protocol-defined inclusion/exclusion criteria may apply

Keywords: ppp
the effect of sumatriptan and placebo injection on cilostazol induced headache

Conditions: Migraine

Summary: to develop a pragmatic migraine model the investigators will induce headache in patients with migraine without aura with a phosphodiesterase inhibitor (cilostazol). if the headache responds to sumatriptan injection, the model can be used to test new drug candidates.

there remains a great need for more effective anti-migraine drugs with fewer side effects. human experimental models are valuable in early phase development of new anti-migraine drugs but useful models have not yet been developed. the investigators' group has shown that cilostazol, a phosphodiesterase inhibitor induce headache/migraine in both healthy volunteers and in patients with migraine without aura (mo). to validate this model, the headache must respond to specific migraine treatment with sumatriptan. hypothesis: cilostazol induces a migraine-like headache in mo-patients and the induced headache responds to sumatriptan injection aim: developing a pragmatic and valid model for the testing of new anti-migraine drugs.

Eligibility criteria:
inclusion criteria: * migraine patients who meet ihs criteria for migraine with or without aura of both sexes * 18-70 years * 45-95 kg. exclusion criteria: * any other type of headache then migraine without aura (except episodic tension-type headache \< 1 day per week) * serious somatic or psychiatric disease * pregnancy * intake of daily medication (except oral contraceptives) * triptan non-responders
impact of gastric length of myotomy during poem on gastroesophageal reflux

Conditions: Gastric Reflux

Summary: this observational study will be conducted among 43 patients of both sexes in each group study participants will be of the age more than 18 years * study procedure-pre-defined technique to avoid bias and confounding due to multiple factors * all the poem procedures will be performed by posterior route * preservation of sling fibers will be attempted in all the cases to avoid heterogeneity * length of esophageal myotomy will be kept constant (4-6cm) * double scope technique will be utilized to confirm the gastric extent of myotomy first evaluation at 1-month: based on symptoms • second evaluation: at 6 months by * objective evaluation: ugi endoscopy, high resolution manometry, timed barium swallow * eckardt score, gerd-hrql * 24-hour ph study with manual readings

• the primary outcome of the study is the incidence of significant reflux esophagitis (≥grade b) in cases with standard and extended gastric myotomies at 6 months after poem secondary outcomes: * significant esophageal acid exposure (\>6%) as defined by the revised lyon consensus * symptoms of gerd (gerd hrql) * clinical efficacy (eckardt score≤3) * esophageal emptying at 5 minutes * high resolution manometry parameters (les pressures and integrated relaxation pressure in mmhg units) * all the secondary outcomes will be assessed at 6 months after poem procedure eligibility: eligible cases with idiopathic achalasia (type i and ii) will be enrolled in the study and randomized (1:1 ratio) in two groups according to the length of gastric myotomies inclusion criteria : * idiopathic achalasia (type i and ii) * age ≥18 years * willing to provide informed consent and comply with the study protocol exclusion criteria * ineligibility for poem procedure * spastic esophageal motility disorders * presence of esophageal diverticulum and hiatal hernia * prior hellers myotomy with or with out fundoplication

Eligibility criteria:
inclusion criteria: * idiopathic achalasia (type i and ii) * age ≥18 years * willing to provide informed consent and comply with the study protocol exclusion criteria: * ineligibility for poem procedure * spastic esophageal motility disorders * presence of esophageal diverticulum and hiatal hernia * prior hellers myotomy with or with out fundoplication
effects of parent-adolescent joint i-interventions for adolescents with adverse childhood experiences

Conditions: Stress-related Problem; Stress, Emotional

Summary: the study aims to examine the effectiveness of internet-based parent-adolescent joint interventions in improving the mental health outcomes of participants, specifically by reducing symptoms of depression, anxiety, and ptsd, as measured by the patient health questionnaire (phq-9), the generalized anxiety disorder-7 scale (gad-7), and the child ptsd symptom scale for dsm-5 (cpss-5). adolescents will be recruited from middle schools and randomly assigned to one of three groups: (a) psychoeducation, (b) psychoeducation + emotional skills enhancement, or (c) psychoeducation + emotional skills enhancement + positive childhood experience promotion. the school-based intervention will consist of 4-8 sessions, with assessments conducted at baseline, post-treatment, and a 3-month follow-up. investigators will conduct multilevel models (mlms) and structural equation models (sems) to investigate the impact of adverse childhood experiences (aces), positive childhood experiences (pces), alexithymia, and emotion regulation abilities on mental health outcomes in adolescents.


Eligibility criteria:
inclusion criteria: * middle school students studying in school and their parents * capable of hearing, speaking, reading, and writing exclusion criteria: * high suicidal risks * severe mental disorders

Keywords: adolescents randomized controlled trial ptsd ace depression anxiety
the value of oral micronized progesterone in the prevention of spontaneous preterm birth

Conditions: Preterm Birth

Summary: this is a randomized, double-blind, placebo-controlled study.

intervention: the study subjects will be randomized to receive twice daily tablets of either 100 mg of omp (uterocare®, october pharma , sixth of october city, egypt) or placebo from enrollment (14-18 weeks) until 36 weeks or delivery, whichever occurs first. the patients and medical staff will be blinded to the study medication allocation. method of randomization: all patients who are fit for admission into the study will pull one of the numbered sealed identical black bags containing either the active medicine (=25%), the placebo (with the aim of admission into data collection, =25%), or a placebo together with a short note explaining that they will not be admitted to the study (=50%) and that they can give back their bag to the head nurse. the code for the 424 (106x4) bag numbers is a confidential computer generated random number list (generated using medcalc© software bvba, ostend, belgium). it will be left, in a sealed envelope, with the head nurse of the antenatal clinic, till the end of data collection.ruptured membranes. 5. obstetric ultrasound for gestational age, amniotic fluid volume, fetal weight, placental position, fetal anomalies. 6. transvaginal ultrasound is not always available for cervical length assessment in asumh, so it will not be a necessary step in patients assessment but will be done whenever available. follow up: patients will be followed up regularly, at twice monthly intervals, in the antenatal clinic of ain shams university maternity hospital until delivery. they will be instructed to return to the hospital when recurrence of symptoms of preterm labor, rupture of membranes, or vaginal bleeding. there will be telephone call follow ups routinely to ensure adherence to the study protocol.

Eligibility criteria:
inclusion criteria: 1. singleton pregnancies. 2. gestational age, on admission, is between 14 and 18 weeks. 3. past history of at least one idiopathic preterm birth. exclusion criteria: 1. established preterm labor (cervical dilatation ≥ 4 cm). 2. persistent uterine contractions. 3. women with medical or surgical complications indicating delivery or termination of pregnancy. 4. presence of fetal anomalies incompatible with life. 5. premature rupture of membranes.

Keywords: preterm birth oral micronized progesterone
safety, tolerability and immunogenicity of meningococcal b recombinant vaccine administered with or without routine infant vaccinations to healthy infants according to different immunization schedules

Conditions: Meningococcal Infections

Summary: primary :1.to demonstrate a sufficient immune response of rmenb+omv nz, when given concomitantly with routine infant vaccines to healthy infants at 2, 4 and 6 and 2, 3 and 4 months of age, as measured by percentage of subjects with serum bactericidal activity (sba) titer ≥1:5, at 1 month after the third vaccination secondary :to demonstrate that immunogenicity of routine infant vaccines, when given concomitantly with rmenb+omv nz to healthy infants at 2, 3 and 4 months of age, was non-inferior to that of routine infant vaccines given without rmenb+omv nz. 2. to demonstrate that the immunogenicity of rmenb+omv nz when given concomitantly with routine infant vaccines was non-inferior to that of rmenb+omv nz given without routine infant vaccines at 2, 4 and 6 months of age. 3. to assess prevalence of meningococcal b antibodies over the study period by evaluation of sba, at baseline and at 1 month after third vaccination, in subjects- received routine infant vaccine without rmenb+omv nz.


Eligibility criteria:
inclusion criteria: * healthy 2-month old infants (55-89 days, inclusive), who were born after full term pregnancy with an estimated gestational age ≥ 37 weeks and a birth weight ≥ 2.5 kg; * for whom a parent/legal guardian has given written informed consent after the nature of the study has been explained. exclusion criteria: * history of any meningococcal b or c vaccine administration; * prior vaccination with routine infant vaccines (diphtheria, tetanus, pertussis, polio, haemophilus influenzae type b (hib), and pneumococcal antigens); * previous ascertained or suspected disease caused by n. meningitidis; * history of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component; * significant acute or chronic infection within the previous 7 days or axillary temperature major or equal to38 degrees within the previous day; * antibiotics within 6 days prior to enrollment; * any serious chronic or progressive disease; * known or suspected impairment or alteration of the immune system; * receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation.

Keywords: meningococcal disease, neisseria meningitidis serogroup b, prevention, vaccination, infants
pilot experimental study: efficacy of paraffin therapy and occupational therapy associated with robotics in patients with erosive osteoarthritis

Conditions: Arthrosis

Summary: this is a randomized, evaluator-blinded, non-profit, single-center, exploratory, medical device clinical trial aimed at evaluating the efficacy in terms of reduction of functional limitation of the combination of occupational therapy, paraffin therapy, and robotic arm mobilization compared to the center's soc, i.e. paraffin therapy and occupational therapy.


Eligibility criteria:
inclusion criteria: * male and female patients aged between 35 and 70 years. * diagnosis of erosive osteoarthritis of the fingers confirmed clinically and radiologically. * presence of persistent functional limitation (at least 6 months) in finger flexion * vas value pain referred only to the hands \> 5 in the week prior to enrollment in the study. * patients not responding to anti-inflammatory and steroid therapy used in the last 2 years. * patients eligible for occupational therapy and paraffin therapy. * signature of the informed consent form for participation in the study and processing of personal data. exclusion criteria: * patients aged \ 70 years. * patients with diagnosis of overlapping arthritic pathologies. * patients undergoing hand surgery in the 6 months prior to the evaluation. * patients with functional alterations to the hands due to trauma. * patients with cognitive or mental disorders. * corticosteroid use within 6 months prior to baseline. * patients unable to use robots with mechanical arms
contrast-free magnetic resonance imaging for breast disease

Conditions: Breast Cancer; Breast Diseases

Summary: prospective, observational cohort study looking at patients either at risk of breast cancer or have clinically suspected breast to assess the diagnostic performance of quantitative, non-contrast mri.

it is widely recognised that mammography is highly sensitive for detecting breast lesions and a valuable tool for early detection of breast cancer, especially in post-menopausal women with non-dense breast tissue. on post-menopausal non-dense breast tissue, mammography is 90% effective at identifying breast tumours. however, for dense breast tissue, the sensitivity falls to 67%. this means that for women with dense breast tissue, which includes almost all pre-menopausal women and many post- menopausal women, mammography misses one third of tumours. mri is the imaging method of choice for detecting breast cancer in women with dense breast tissue however the standard mri for breast cancer investigation typically uses gadolinium contrast agent. this method is called dynamic contrast enhanced (dce) mri and identifies localised regions of (neo)vascularity, which indicates a cancerous lesion. although dce can provide valuable information about the tissue, it is often not performed well, is poorly tolerated by patients, and adds additional time to the scan protocol. perspectum conducted a recent study demonstrating that liver cancer lesions can be identified using quantitative t1 maps calculated form multiparametric mri data. applying this mri method to breast imaging, would potentially provide a method of identifying breast cancer lesions without using a contrast agent, reducing the scan time and eliminating the need for an intravenous contrast. the aim of this study is to apply quantitative multiparametric mri techniques to the area of breast imaging with the aim of developing a contrast-free mr scan which can diagnose the spectrum of breast disease referred to a secondary care breast clinic, including in women with dense breasts.

Eligibility criteria:
inclusion criteria: * female 30 years of age and over * participant has been referred to a secondary care breast screening clinic. * participant is willing and able to give informed consent for participation in the investigation. exclusion criteria * the participant may not enter the study with any known contraindication to magnetic resonance imaging (including but not limited to a pacemaker or other metallic unfixed implanted device, metallic fragments, extensive tattoos, severe claustrophobia). * any other cause, including a significant underlying disease or disorder which, in the opinion of the investigator, may put the participant at risk by participating in the study or limit the participant's ability to participate.

Keywords: breast imaging magnetic resonance imaging screening